Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer

Purpose To evaluate the efficacy and safety of erlotinib in advanced breast cancer. Experimental design Multicenter, phase II study of erlotinib (150 mg orally daily). Cohort 1: progression after anthracyclines, taxanes, and capecitabine (n = 47). Cohort 2: progression after >1 chemotherapy for a...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research and treatment 2009-05, Vol.115 (1), p.115-121
Main Authors: Dickler, Maura N, Cobleigh, Melody A, Miller, Kathy D, Klein, Pamela M, Winer, Eric P
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Anthracyclines - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Breast cancer
Breast Neoplasms - drug therapy
Cancer research
Cancer therapies
Capecitabine
Chemotherapy
Clinical outcomes
Clinical Trial
Clinical trials
Cohort Studies
Deoxycytidine - administration & dosage
Deoxycytidine - analogs & derivatives
Disease Progression
Epidermal growth factor receptor (EGFR/HER1)
Erlotinib
Erlotinib Hydrochloride
Female
Fluorouracil - administration & dosage
Fluorouracil - analogs & derivatives
Gynecology. Andrology. Obstetrics
Humans
Mammary gland diseases
Medical sciences
Medicine
Medicine & Public Health
Metastatic breast cancer
Middle Aged
Neoplasm Metastasis
Oncology
Patient selection
Prescription drugs
Protein Kinase Inhibitors - therapeutic use
Quinazolines - therapeutic use
Receptor, Epidermal Growth Factor - metabolism
Taxoids - administration & dosage
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To evaluate the efficacy and safety of erlotinib in advanced breast cancer. Experimental design Multicenter, phase II study of erlotinib (150 mg orally daily). Cohort 1: progression after anthracyclines, taxanes, and capecitabine (n = 47). Cohort 2: progression after >1 chemotherapy for advanced-stage disease (n = 22). Primary endpoint was response rate (World Health Organization criteria). Secondary endpoints were safety, time to progression, and survival. Results One patient in each cohort (n = 2, 3.0%) had a partial response. Response duration was 17 weeks for the Cohort 1 patient and 32 weeks for the Cohort 2 patient. Median time to progression was 43 days for Cohort 1 (range 1-204) and 43 days for Cohort 2 (range 25-419). Common adverse events were diarrhea, rash, dry skin, asthenia, nausea, anorexia. Conclusion Erlotinib had minimal activity in unselected previously treated women with advanced breast cancer. Predictive factors are needed to identify breast cancer patients who may derive benefit from erlotinib treatment.
ISSN:0167-6806
1573-7217
DOI:10.1007/s10549-008-0055-9